Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 4 of the last 4 fiscal years.
-
Tight liquidity NBB
Cash and receivables cover 40 % of short-term debt in 2025; threshold 65 %.
-
Busy address KBO
19 other companies have their registered office at the same address; threshold 10.
-
Legal situation KBO
Vrijwillige ontbinding – vereffening according to the CBE.
Financials
Financial year 2025
Aelin Therapeutics from Brugge, company number BE0685688842, closed financial year 2025 with a result of € 313,335 after tax. For that financial year Aelin Therapeutics recorded revenue of € 30,000 and equity of € -3.2 million. Compared with financial year 2024, the result moved from € 41,100 to € 313,335. Profitable, and profit is growing. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 10, 2026.
€ -3.2 million
▲ € 313,335 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 313,335
▲ € 272,234 vs 2024
Profit after tax over the fiscal year.
€ 1.8 million
▲ 15% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € -29.1 million.
Debts at end 2025
€ 5 million
Loans from banks and other lenders, long and short.
€ 208,959
▼ 13% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 2904 days on average.
| 2023 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 3,669 | € 234 | - | € 30,000 | |
| Profit after taxes | € -6,695,833 | € 411,634 | € 41,100 | € 313,335 | ▲ € 272,234 |
| Equity | € -3,989,795 | € -3,578,162 | € -3,537,061 | € -3,223,727 | ▲ € 313,335 |
| Total debts | € 6,321,340 | € 5,390,875 | € 5,338,274 | € 5,306,134 | ▼ 1% |
| Cash | € 2,556,688 | € 1,291,411 | € 1,573,038 | € 1,802,611 | ▲ 15% |
| Retained profit | € -29,823,125 | € -29,411,492 | € -29,370,391 | € -29,057,057 | ▲ € 313,335 |
| Bank debt | € 5,128,194 | € 5,000,000 | € 5,000,000 | € 5,000,000 | |
| Balance sheet total | € 3,718,041 | € 1,908,890 | € 1,829,513 | € 2,098,207 | ▲ 15% |
| Employees (FTE) | 28.3 | 1 | - | - |
Key figures of Aelin Therapeutics, fiscal years 2023 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Aelin Therapeutics?
What happened at Aelin Therapeutics in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
Aelin Therapeutics is active according to the CBE. Legal situation: Vrijwillige ontbinding – vereffening.
- New annual accounts for financial year 2025: profit of € 313,335 (▲ € 272,234 vs 2024). filed late Source: NBB ↗
- Dave Pardo became a director. NBB
- Pieter Van Aerschot became a director. NBB
- New establishment in Gent. KBO
- New establishment in Leuven. KBO
- Start of the company according to the CBE. KBO
In short
From € 6.7 million loss in 2023 to € 313,335 profit in 2025.
Paid € 942,627 in corporate taxes since 2023.
Best year ever: 2023, with € 411,634 profit.
Management
Behind Aelin Therapeutics are Dave Pardo and Pieter Van Aerschot. The shares are held by LSP V Coöperatieve LLA (30.9%), Fund+ NV (19.9%), Boehringer Ingelheim Venture Fund GmbH (16.9%), BFV NV (16%), Vlaams Interuniversitair Instituut voor Biotechnologie VZW (12%) and PMV NV (4%).
Directors
According to the 2025 annual accounts
since 2023
since 2023
Shareholders
LSP V Coöperatieve LLA
30.9%
19.9%
16%
4%
Novartis Bioventures Ltd
0.3%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Lieven Bauwensstraat 20
8200 Brugge
Gaston Geenslaan 1
3001 Leuven
Active since 6 December 2017
Technologiepark-Zwijnaarde 73A
9052 Gent
Active since 15 January 2021
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 19 companies are registered at this address.
All companies at this address →Koninklijke Vlaamse Krachtbalfederatie
BEDRIJVENCENTRUM REGIO BRUGGE
€ 117,037 gross margin · 2025
FLIN same network
€ 289,646 gross margin · 2025
BOUWONDERNEMING SANDERS
DANSPLATOO
+14 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0685.688.842
- VAT number
- BE 0685.688.842
- Registered office
- Lieven Bauwensstraat 20, 8200 Brugge
- Names & denominations
- Aelin Therapeutics
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Vrijwillige ontbinding – vereffening
- Start date
- 6 December 2017
- Peppol
- Active · Active since 5 Nov 2025
- Activities · NACE
Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg
Overige gespecialiseerde wetenschappelijke en technische activiteiten
Activiteiten van medische beeldvorming en medische laboratoria
Activiteiten van medische laboratoria